> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Replimune Stock Jumps 9.73% After First Quarter Selling Its Melanoma Drug Tudriqev
- URL: https://www.bullished.co/replimune-stock-jumps-9-73-after-first-quarter-selling-its-melanoma-drug-tudriqev-f2c33eff/
- Published: 2026-10-28T14:57:29.000Z
- Updated: 2026-10-29T10:06:35.000Z
- Description: The cancer-drug developer reported a $57.1 million quarterly net loss and said more than 15 institutions are prescribing Tudriqev.
- Author: Matteo Parrino
- Tags: Markets, REPL, Industry: Healthcare

[Replimune Group](https://www.bullished.co/tag/repl/), which develops cancer treatments built on an engineered herpes virus, climbed 9.73% to $14.32 in Wednesday trading, as of 10:56 a.m. ET, adding about $120 million in market value. The move came the day it [reported fiscal second-quarter results](https://www.globenewswire.com/news-release/2026/10/28/3390022/0/en/replimune-reports-fiscal-second-quarter-2027-financial-results-and-provides-corporate-update.html?ref=bullished.co) and said its melanoma drug Tudriqev has reached patients.

## A launch with 15 prescribers

[More than 15 institutions](https://www.globenewswire.com/news-release/2026/10/28/3390022/0/en/replimune-reports-fiscal-second-quarter-2027-financial-results-and-provides-corporate-update.html?ref=bullished.co) are now prescribing Tudriqev, the company said. Management told investors on its earnings call that the launch is going very well and that it is eyeing a doubling of treating accounts by year-end.

The company offered formulary and first-script counts rather than patient numbers or revenue guidance. It said it has actively engaged 70% of its initial 200 priority accounts to set up workflows for adopting the drug.

Tudriqev was first delivered to patients on October 6, and the company says it holds more than a year of inventory made in its own facility.

## Loss and cash position

The company's [quarterly filing](https://www.sec.gov/Archives/edgar/data/1737953/000162828026067722/repl-20260930.htm?ref=bullished.co) shows a net loss of $57.1 million for the period ended September 30\. Cash and cash equivalents stood at $307.8 million at the end of September, including about $141.0 million in net proceeds from a stock and pre-funded warrant offering.

## A third straight gain

Replimune, a clinical-stage company, had no approved products before Tudriqev. Its second candidate, RP2, is being studied in uveal melanoma, a cancer of the eye, and in liver cancers.

The stock was on pace for its third straight daily gain and its biggest one-day rise since August 12, when it gained 11.6%. Shares were up about 34% for the year as of Tuesday's close, against about 13% for the S&P 500.

Replimune's next scheduled earnings date is Wednesday, November 4.

*Correction, Oct. 29, 2026: An earlier version of this story linked a statement from the company's earnings call to a page that did not contain it. The link has been removed.*

### Sources

- [Replimune Group GAAP EPS of -$0.54 beats by $0.21 (REPL:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4658779-replimune-group-gaap-eps-of-0%5F54-beats-by-0%5F21?ref=bullished.co) — seekingalpha.com
- [Replimune Reports Fiscal Second Quarter 2027 Financial](https://www.globenewswire.com/news-release/2026/10/28/3390022/0/en/replimune-reports-fiscal-second-quarter-2027-financial-results-and-provides-corporate-update.html?ref=bullished.co) — globenewswire.com
- [The company's filing (Replimune Group)](https://www.sec.gov/Archives/edgar/data/0001737953/000110465926119354/tm2628395d1%5F8k.htm?ref=bullished.co) — SEC filing
- [Replimune Group — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1737953/000162828026067722/repl-20260930.htm?ref=bullished.co) — SEC EDGAR

### More on Replimune Group

- [Replimune Says Tudrakev Accounts Could Double By Year-End, With Some Hospitals Skipping Formulary Review](https://www.bullished.co/replimune-says-tudrakev-accounts-could-double-by-year-end-with-some-hospitals-skipping-140014e6/)
- [Replimune Counts Accounts, Not Patients, For Its Tudrakev Launch — And Offers No Revenue Guidance](https://www.bullished.co/replimune-counts-accounts-not-patients-for-its-tudrakev-launch-and-offers-no-revenue-e51a69d3/)
- [Replimune's $97.9 Million Hercules Loan Now Carries A $1.2 Billion Market-Cap Test](https://www.bullished.co/replimunes-97-9-million-hercules-loan-now-carries-a-1-2-billion-market-cap-test-c1eafddc/)

[All Replimune Group (REPL) coverage →](https://www.bullished.co/tag/repl/)